Leslie Stolz
General Counsel at VERVE THERAPEUTICS, INC.
Leslie Stolz active positions
| Companies | Position | Start | End |
|---|---|---|---|
| VERVE THERAPEUTICS, INC. | General Counsel | 2019-05-31 | - |
Career history of Leslie Stolz
Former positions of Leslie Stolz
| Companies | Position | Start | End |
|---|---|---|---|
Syntimmune, Inc.
 Syntimmune, Inc. BiotechnologyHealth Technology Syntimmune, Inc. engages in the research and development of therapeutics for autoimmune diseases based on neonatal Fc receptor biology. Its pipeline include SYNT001 which has target indication for dermatology, hematology, and neurology. It also focuses on pre-clinical investigation of SYTN002 and related compounds such as peptide mimetics. The company was founded by Laurence J. Blumberg and Richard S. Blumberg in 2013 and is headquartered in Boston, MA. | Corporate Officer/Principal | - | 2017-12-31 |
Training of Leslie Stolz
| Duke University | Doctorate Degree |
| Villanova University | Undergraduate Degree |
Statistics
International
| United States | 5 |
Operational
| General Counsel | 1 |
| Corporate Officer/Principal | 1 |
| Doctorate Degree | 1 |
Sectoral
| Health Technology | 3 |
| Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| VERVE THERAPEUTICS, INC. | Health Technology |
| Private companies | 1 |
|---|---|
Syntimmune, Inc.
Syntimmune, Inc. BiotechnologyHealth Technology Syntimmune, Inc. engages in the research and development of therapeutics for autoimmune diseases based on neonatal Fc receptor biology. Its pipeline include SYNT001 which has target indication for dermatology, hematology, and neurology. It also focuses on pre-clinical investigation of SYTN002 and related compounds such as peptide mimetics. The company was founded by Laurence J. Blumberg and Richard S. Blumberg in 2013 and is headquartered in Boston, MA. | Health Technology |
- Stock Market
- Insiders
- Leslie Stolz
- Experience
